Twist Bioscience Corp (OQ:TWST)
Business Focus: Biopharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 681 Gateway Blvd. SOUTH SAN FRANCISCO CA 94080 |
| Tel: | N/A |
| Website: | https://www.twistbioscience.com |
| IR: | See website |
| Key People | ||
| Emily M. Leproust Chairman of the Board, Chief Executive Officer | Chet Gandhi Chief Information Officer | Patrick John Finn President, Chief Operating Officer |
| Adam Laponis Chief Financial Officer | Dennis Cho Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer | William Banyai Senior Vice President - Advanced Development, General Manager of Data Storage and Director |
| Paula Green Senior Vice President - Human Resources | Tracey Mullen Senior Vice President - Biopharma | Siyuan Chen Chief Technology Officer | Robert Werner Chief Accounting Officer, Vice President |
| Business Overview |
| Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools. |
| Financial Overview |
| For the three months ended 31 December 2023, Twist Bioscience Corp revenues increased 32% to $71.5M. Net loss increased 3% to $43M. Revenues reflect NGS tools segment increase of 62% to $39.4M, Synthetic genes segment increase of 22% to $19.7M, Americas segment increase of 31% to $44M, EMEA segment increase of 30% to $21.2M. Higher net loss reflects Stock-based Compensation in SGA increase from $7.9M (income) to $7.3M (expense). |
| Employees: | 919 as of Sep 30, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,329M as of Dec 31, 2023 |
| Annual revenue (TTM): | $262.36M as of Dec 31, 2023 |
| EBITDA (TTM): | -$171.12M as of Dec 31, 2023 |
| Net annual income (TTM): | -$205.80M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$128.84M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 57,818,022 as of Jan 29, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.